Research programme: hepatitis C virus NS4A protein inhibitors - Achillion

Drug Profile

Research programme: hepatitis C virus NS4A protein inhibitors - Achillion

Alternative Names: ACH-1095; GS-9525; Hepatitis C virus NS4A antagonists - Achillion

Latest Information Update: 04 Jun 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Fluorine compounds; Pyridazines; Small molecules; Thiazoles
  • Mechanism of Action Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 04 Jun 2013 Discontinued - Preclinical development of HCV NS4A protein inhibitors for Hepatitis C in USA (PO) before June 2013
  • 29 Feb 2012 Gilead terminates its collaboration and licensing agreement with Achillion for hepatitis C virus NS4A antagonists
  • 20 Aug 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top